- Partner Sanofi advances SAR443579 / IPH6101, ANKET® platform
lead asset, a trifunctional anti-CD123 NKp46xCD16 NK cell engager,
to Phase 2 dose expansion in blood cancers
- Dosing of the first patient in the dose expansion part of
the trial triggers a €4m milestone payment to Innate
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate”
or the “Company”) today announced that the first patient was dosed
in the Phase 2 dose expansion part of the Sanofi-sponsored clinical
trial of SAR443579 / IPH6101 (NCT05086315), evaluating SAR443579 as
a monotherapy for the treatment of blood cancers with high unmet
needs, including relapsed or refractory acute myeloid leukemia (R/R
AML), B-cell acute lymphoblastic leukemia and high-risk
myelodysplasia.
SAR443579 is an investigational trifunctional anti-CD123
NKp46xCD16 NK cell engager from a joint research collaboration
between Innate Pharma and Sanofi. SAR443579 received FDA Fast Track
Designation for the treatment of acute myeloid leukemia. Efficacy
and safety results from the dose-escalation part of the trial were
shared in a poster presentation at the American Society of
Hematology 2023 Annual Meeting in San Diego, California.
“The progression of SAR443579 to the Phase 2 expansion part of
the clinical trial in blood cancers is another step in bringing
this innovative NK cell engager to patients,” said Dr. Sonia
Quaratino, Chief Medical Officer of Innate Pharma. “SAR443579
has shown promising clinical efficacy in the dose escalation of the
Phase 1/2 in R/R AML patients, and we look forward to the dose
expansion part of the study."
Under the terms of the 2016 research collaboration with Sanofi,
the progression to the dose expansion part of the trial has
triggered a milestone payment from Sanofi to Innate of €4m.
“Our goal is to continue to develop the best and most impactful
treatments for patients with cancer,” said Peter Adamson, Global
Development Head, Oncology, Sanofi.“We are encouraged by our
progress in this study for patients with AML, and look forward to
sharing results in the future as data continues to emerge.”
More information about the Phase 1/2 trial can be found on
clinicaltrials.gov.
About ANKET®
ANKET® (Antibody-based NK cell Engager
Therapeutics) is Innate's proprietary platform for
developing next-generation, multi-specific natural killer (NK) cell
engagers to treat certain types of cancer.
This versatile, fit-for-purpose technology is creating an
entirely new class of molecules to induce synthetic immunity
against cancer.
About the Innate-Sanofi research collaboration and licensing
agreements
The Company has a research collaboration and license agreement
with Sanofi to apply Innate’s proprietary technology to the
development of innovative multi-specific antibody formats engaging
NK cells through the activating receptors NKp46 and CD16 to kill
tumor cells.
Under the terms of the 2016 research collaboration and license
agreement, Sanofi is responsible for the development, manufacturing
and commercialization of products resulting from the research
collaboration, which includes SAR443579/IPH6101 (Trifunctional
anti-CD123 NKp46xCD16 NK cell engager) and SAR445514/IPH6401
(Trifunctional anti-BCMA NKp46xCD16 NK cell engager). As part of
the 2016 agreement, Innate Pharma is eligible to up to €400m in
development and commercial milestone payments as well as royalties
on net sales.
As part of the license agreement entered in December 2022,
Sanofi licensed IPH62 and IPH67 and has the option for one
additional target. Under the terms of the 2022 agreement, Innate
Pharma is eligible to up to €1.35bn total in preclinical, clinical,
regulatory and commercial milestones plus royalties on potential
net sales.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology
company developing immunotherapies for cancer patients. Its
innovative approach aims to harness the innate immune system
through therapeutic antibodies and its ANKET®
(Antibody-based NK cell Engager
Therapeutics) proprietary platform.
Innate’s portfolio includes lead proprietary program lacutamab,
developed in advanced form of cutaneous T cell lymphomas and
peripheral T cell lymphomas, monalizumab developed with AstraZeneca
in non-small cell lung cancer, as well as ANKET® multi-specific NK
cell engagers to address multiple tumor types.
Innate Pharma is a trusted partner to biopharmaceutical
companies such as Sanofi and AstraZeneca, as well as leading
research institutions, to accelerate innovation, research and
development for the benefit of patients.
Headquartered in Marseille, France with a US office in
Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq
in the US.
Learn more about Innate Pharma at www.innate-pharma.com and
follow us on X and LinkedIn.
Information about Innate Pharma shares
ISIN code Ticker code
LEI
FR0010331421
Euronext: IPH Nasdaq: IPHA
9695002Y8420ZB8HJE29
Disclaimer on forward-looking information and risk
factors
This press release contains certain forward-looking statements,
including those within the meaning of the Private Securities
Litigation Reform Act of 1995. The use of certain words, including
“believe,” “potential,” “expect” and “will” and similar
expressions, is intended to identify forward-looking statements.
Although the company believes its expectations are based on
reasonable assumptions, these forward-looking statements are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. These
risks and uncertainties include, among other things, the
uncertainties inherent in research and development, including
related to safety, progression of and results from its ongoing and
planned clinical trials and preclinical studies, review and
approvals by regulatory authorities of its product candidates, the
Company’s commercialization efforts and the Company’s continued
ability to raise capital to fund its development. For an additional
discussion of risks and uncertainties which could cause the
company's actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque")
section of the Universal Registration Document filed with the
French Financial Markets Authority (“AMF”), which is available on
the AMF website http://www.amf-france.org or on Innate Pharma’s
website, and public filings and reports filed with the U.S.
Securities and Exchange Commission (“SEC”), including the Company’s
Annual Report on Form 20-F for the year ended December 31, 2023,
and subsequent filings and reports filed with the AMF or SEC, or
otherwise made public, by the Company.
This press release and the information contained herein do not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe to shares in Innate Pharma in any country.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240414715190/en/
For additional information, please contact:
Investors Innate Pharma
Henry Wheeler Tel.: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr
Media Relations
NewCap Arthur Rouillé Tel.: +33 (0)1 44 71 00 15
innate@newcap.eu
Innate Pharma (NASDAQ:IPHA)
Historical Stock Chart
From Apr 2024 to May 2024
Innate Pharma (NASDAQ:IPHA)
Historical Stock Chart
From May 2023 to May 2024